Topics

Enterprise Therapeutics Ltd Company Profile

03:19 EST 24th January 2020 | BioPortfolio

Enterprise Therapeutics is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.


News Articles [882 Associated News Articles listed on BioPortfolio]

Enterprise Therapeutics publishes open access paper on novel approach to treat cystic fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease,...

Valley Health System Becomes First Health System in New Jersey to Prescribe Enterprise-wide Digital Therapeutics

– Valley Health System becomes the first health system in New Jersey to prescribe enterprise-wide digital therapeutics in partnership with Mount Sinai Health System spinoff Rx Health. – Th...

University of Birmingham Enterprise welcomes progress in new treatment for Idiopathic Intracranial Hypertension (IIH)

5 July 2019: University of Birmingham Enterprise welcomes the floatation of Invex Therapeutics, which is developing an innovative new treatment approach for IIH discovered at the University of Birming...

Enterprise Therapeutics Awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator

Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients Milestone Funding through Cystic Fibrosis Fo...

Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients

“TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine Paper demonstrates first in cl...

Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator.

Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients Milestone Funding through Cystic Fibrosi...

Enterprise and LyondellBasell Partner on PDH

Enterprise Products Partners and LyondellBasell have signed long-term contracts that will support the construction of Enterprises’s second propane dehydrogenation (PDH) plant in Mont Belvieu, Te...

Platelet BioGenesis receives $2.3 million award from Medical Technology Enterprise Consortium

Platelet BioGenesis, the leader in stem cell-derived, on-demand human platelets (PLTs+) and genetically engineered platelet-based therapeutics, announced today it received an award of $2.3 million fro...

Drugs and Medications [30 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [457 Associated PubMed Articles listed on BioPortfolio]

Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke.

Digital therapeutics is an evidence-based intervention using high-quality software, with the sole purpose of treatment. As many healthcare systems are encountering high demands of quality outcomes, th...

Understanding the role of environmental quality attributes in food-related rural enterprise competitiveness.

This paper examines the role of environmental quality attributes in food-related rural enterprise competitiveness in Denmark, using qualitative interviews. The results of the analysis demonstrate that...

An investigation of occupational exposure to welding fume, manganese, and manganese compounds in a large container manufacturing enterprise.

To investigate the current status of the occupational hazards of welding fume, manganese, and manganese compounds in the welding environment of a large container manufacturing enterprise, as well as t...

Does command-and-control regulation promote green innovation performance? Evidence from China's industrial enterprises.

Many developing countries including China have launched command-and-control regulation (CCR) to achieve sustainable development. However, we know little about whether CCR promotes green innovation per...

Measurement of mRNA therapeutics: method development and validation challenges.

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for t...

Clinical Trials [222 Associated Clinical Trials listed on BioPortfolio]

Enterprise Stent Implantation in the Treatment of Carotid Artery Stenosis With Ischemic Stroke

To investigate the long-term effects of intracranial implantation of Enterprise stent system versus antiplatelet medication on neurologic deficits, daily living abilities, and carotid arte...

The ENTERPRISE Study - Study of the Enterprise Self-Expanding Stent System

To evaluate the safety and feasibility of the Cordis Neurovascular Self-Expanding Stent System to facilitate endovascular coil embolization of wide neck saccular intracranial aneurysms. ...

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Companies [2222 Associated Companies listed on BioPortfolio]

Enterprise Therapeutics Ltd

Enterprise Therapeutics is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.

Solace Therapeutics Inc.

Solace Therapeutics is dedicated to developing innovative, non-surgical and clinically effective devices that address unmet needs in lower urinary tract symptoms (LUTS). Our initi...

Coveo

Coveo is a leader in enterprise search-powered solutions. The Coveo Enterprise Search Platform and Customer Information Access Solutions help organizations generate value from information and knowled...

ServiceNow

ServiceNow is the enterprise IT cloud company. We focus on transforming enterprise IT by automating and standardizing business processes and consolidating IT across the global ent...

Hummingbird Ltd

Hummingbird Ltd. (NASDAQ: HUMC, TSX: HUM) is a leading global provider of enterprise software solutions. Our enterprise content management (ECM) solutions allow customers to manage the entire lifecycl...

More Information about "Enterprise Therapeutics Ltd" on BioPortfolio

We have published hundreds of Enterprise Therapeutics Ltd news stories on BioPortfolio along with dozens of Enterprise Therapeutics Ltd Clinical Trials and PubMed Articles about Enterprise Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Enterprise Therapeutics Ltd Companies in our database. You can also find out about relevant Enterprise Therapeutics Ltd Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record